Frontlight ResearchEarly access
CompletedPhase 2
A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)
Key facts
- Who runs it
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 165 people enrolled
- Started
- 20 Jul 2023
- Ended
- 19 Jan 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Genakumab for injection
- Colchicine
- Record updated
- 1 January 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Other criteria
- Signed written informed consent before any study procedure is performed
- Male or female, 18 years ≤ age ≤ 75 years
- BMI ≤ 40kg/m2
- Confirmed diagnosis of gout meeting the American College of Rheumatology (ACR) 2015 preliminary criteria for the classification of arthritis of primary gout
- History of ≥2 gout flare within 12 months prior to screening
- Willingness to initiate urate-lowering therapy or having initiated urate-lowering therapy within 1 week prior to screening
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the safety and efficacy of Genakumab in prevention of acute flares in gout patients initiating urate-lowering therapyurate-lowering
The 2 groups in the trial
- Genakumab groupTreatment being tested
Genakumab 100mg single injection、Genakumab 200mg single injection
Treatment: Genakumab for injection
- Colchicine groupExisting treatment, for comparison
Oral colchicine 0.5mg once a day for 12 weeks
Treatment: Colchicine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Open-lable, Multi-center, Active-controlled Phase 2 Study for Evaluating Efficacy and Safety of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering
- Record updated
- 1 January 2025